(:Q)
Business Focus: N/A
Nov 09, 2017 08:00 am ET
Research Report Identifies Quintiles IMS Holdings, CommScope, KapStone Paper and Packaging, Cadence, ILG, and PBF with Renewed Outlook – Fundamental Analysis, Calculating Forward Movement
NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Quintiles IMS Holdings, Inc. (NYSE:Q), CommScope...
Nov 07, 2017 08:00 am ET
IQVIA Institute for Human Data Science Study: Impact of Digital Health Grows as Innovation, Evidence and Adoption of Mobile Health Apps Accelerate
The impact of Digital Health on patient care is accelerating with the
increasing adoption of mobile health apps and wearable sensors.
Health-related mobile applications available to consumers now surpass
318,500 — nearly double the number available just two years ago — with
approximately 200 new apps added to the market each day. This rapid app
expansion, coupled with more than 340 consumer wearable devices on the
market worldwide, and 571 published efficacy studies, provide evidence
of Digital Health’s accelerating innovation and generation of
Nov 06, 2017 03:53 pm ET
QuintilesIMS is now IQVIA
QuintilesIMS (NYSE:Q) today announced that it will be changing its name
to IQVIA, a company dedicated to using analytics and science to help
healthcare stakeholders find better solutions for their patients,
effective November 6, 2017. Beginning on November 15, 2017, equity
shares of the company will trade on the NYSE under the new name and new
ticker symbol “IQV.” Until then, IQVIA will continue to be listed under
QuintilesIMS and symbol “Q” per the listing notification requirements of
the NYSE.
Nov 06, 2017 08:00 am ET
QuintilesIMS is now IQVIA
QuintilesIMS (NYSE:Q) today announced that it will be changing its name
to IQVIA, a company dedicated to using analytics and science to help
healthcare stakeholders find better solutions for their patients,
effective November 6, 2017. Beginning on November 15, 2017, equity
shares of the company will trade on the NYSE under the new name and new
ticker symbol “IQV.” Until then, IQVIA will continue to be listed under
QuintilesIMS and symbol “Q” per the listing notification requirements of
the NYSE.
Oct 26, 2017 07:00 am ET
QuintilesIMS Reports Third-Quarter 2017 Results
Quintiles IMS Holdings, Inc. (NYSE:Q), a leading global provider of
information, technology solutions and contract research services to the
healthcare and life sciences industries, today reported financial
results for the quarter ended September 30, 2017. On October 3, 2016,
the merger of Quintiles Transnational Holdings Inc. and IMS Health
Holdings, Inc. was completed. To aid investors and analysts with
year-over-year comparability for the merged business, we are including
company financial information that combines the stand-alone Quintiles
Oct 12, 2017 04:15 pm ET
QuintilesIMS to Announce Third-Quarter 2017 Results on October 26, 2017
Quintiles IMS Holdings, Inc. (“QuintilesIMS”) (NYSE:Q) will announce its
third-quarter 2017 financial results before the market opens on
Thursday, October 26, 2017. The QuintilesIMS management team will also
host a conference call and webcast at 9:00 a.m. Eastern Time on that
date. The earnings release and accompanying financial information will
be posted on the QuintilesIMS Investor Relations website at
Oct 04, 2017 04:15 pm ET
QuintilesIMS to Host Financial Analyst and Investor Conference on November 8, 2017
Quintiles IMS Holdings, Inc. (“QuintilesIMS”) (NYSE:Q) will host an
Analyst and Investor Conference in New York City on Wednesday, November
8, 2017. Management will provide an update on the business and progress
since the merger. The presentations will begin at 9:00 a.m. ET and will
conclude at approximately 1:00 p.m. Registration is required to attend
the event.
Aug 24, 2017 07:13 pm ET
Charter Communications Set to Join S&P 100; Quintiles IMS Holdings and SBA Communications to Join S&P 500
NEW YORK, Aug. 24, 2017 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 100 and S&P 500 indices:
Dec 14, 2016 12:05 pm ET
For Second Consecutive Year, U.S. Gastroenterologists Endorse IBgard® As The #1 Recommended Peppermint Oil For IBS...By Overwhelming Margin
BOCA RATON, Fla., Dec. 14, 2016 /PRNewswire/ -- IM HealthScience®, innovators of IBgard®, a medical food using a novel approach in managing irritable bowel syndrome (IBS), announced today results of a nationwide survey conducted among 202 U.S. gastroenterologists by QuintilesIMS using its ProVoice survey methodology. For the second consecutive year, IBgard® continues to be the #1 recommended peppermint oil for IBS among gastroenterologists by an overwhelming margin.
Jun 17, 2016 10:19 am ET
INVESTOR ALERT: Levi & Korsinsky, LLP Announces a Class Action has Been Commenced Challenging the Fairness of the Sale of IMS Health Holdings, Inc. to Quintiles Transnational Holdings, Inc. -- IMS
NEW YORK, June 17, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:...
May 04, 2016 12:54 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation as to Whether the Sale of IMS Health Holdings, Inc. to Quintiles Transnational Holdings, Inc. is Fair to Shareholders -- IMS
NEW YORK, May 4, 2016 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP:
May 02, 2016 08:00 am ET
Novogen Provides Update On Development Of Cantrixil
SYDNEY, May 2, 2016 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today provided an update on progress regarding the development of Cantrixil (TRXE-002-1), its lead superbenzopyran (SBP) molecule, which is intended for the treatment of ovarian cancer.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.